ArticleArthritis & rheumatology (Hoboken, N.J.)2026

Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients With Systemic Lupus Erythematosus and Lupus Nephritis.

April Jorge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.